U.S., Nov. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07229261) titled 'MitoQ to Improve Vascular Funciton in Preeclampsia' on Nov. 13.
Brief Summary: Preeclampsia is a leading cause of maternal and neonatal morbidity and mortality. There is a lack of effective therapeutics for prevention or treatment. Our previous ex vivo work demonstrated that mitochondrial-antioxidants can reverse placental microvascular damage. Therefore, this study will evaluate whether MitoQ (Mitoquinol Mesylate, a mitochondrial-antioxidant) has the potential to restore vasodilation, improve placental function, and therefore promote pregnancy prolongation in patients with preeclampsia. This evaluation of clinical data, patient sam...